<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010604</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA,ECFAHOFFMU[2019]196</org_study_id>
    <nct_id>NCT04010604</nct_id>
  </id_info>
  <brief_title>A Registered Cohort Study on SMA</brief_title>
  <official_title>A Registered Cohort Study on Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wan-Jin Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive
      muscle wasting and weakness due to loss of motor neurons in the spinal cord. This is a
      registered cohort of spinal muscular atrophy (SMA) type Iï¼ŒII and III in China. This study
      will provide further insights into the clinical course of SMA including overall survival,
      demographic characteristics, motor function, respiratory support, feeding and nutritional
      support, growth and development. The correlation of genotype and phenotype will be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2049</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2039</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The time to death</measure>
    <time_frame>From date of enrollment until the date of death from any cause, assessed up to 20years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of genotype and phenotype</measure>
    <time_frame>From date of enrollment until the date of death from any cause, assessed up to 20years</time_frame>
    <description>Genotype is defined by survival motor neuron (SMN) 2 copy number(s) and phenotype is defined by clinical types and characteristics.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>SMA type I</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SMA type II</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SMA type III</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic carriers of SMA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatives of SMA patients and carriers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        SMA patients are diagnosed with SMN1 gene deletion or mutation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SMA types I, II and III

          -  Asymptomatic SMA carriers

          -  Relatives of SMA patients or carriers

          -  Unrelated healthy controls

          -  Participants or Parent(s)/legal guardian(s) willing and able to complete the informed
             consent process

        Exclusion Criteria:

        * Participants are unable to comply with trial procedures and visit schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Lin, PhD</last_name>
    <phone>86-0591-87982772</phone>
    <email>linyi7811@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wan-Jian Chen, PhD</last_name>
    <phone>86-0591-87982772</phone>
    <email>wanjinchen75@fjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, First Affiliated Hospital Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Jin Chen, PhD</last_name>
      <phone>86-0591-87982772</phone>
      <phone_ext>+1386061359</phone_ext>
      <email>wanjinchen75@fjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wan-Jin Chen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ning Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Wan-Jin Chen</investigator_full_name>
    <investigator_title>The Vice-Director for the Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

